Reports Q1 product revenue $2.21M vs $2.35M last year. Mytesi prescription volume increased by approximately 1.8% in Q1 2025 over Q1 2024 and decreased by approximately 13.5% in Q1 2025 over Q4 2024.
Don’t Miss TipRanks’ Half Year Sale
- Take advantage of TipRanks Premium for 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JAGX:
- Jaguar Health Highlights Promising Crofelemer Study Results
- Jaguar Health provides overview of 2025 crofelemer-related catalysts
- Jaguar Health’s Napo reports initial PoC results from trial of crofelemer
- Jaguar Health Announces Promising Crofelemer Trial Results
- Biotech Alert: Searches spiking for these stocks today